Neuroscience trials increasingly depend on non-clinical measures from early-stage development through pivotal trials. The introduction of diagnosis is done by gene, blood, cerebrospinal fluid (CSF) and imaging measures as well as accelerated approval with biomarker surrogate endpoints. Navigating this new landscape requires an integrated contract research organization (CRO) strategy for the development program and trials at each stage of the process.
In this webinar, Medpace experts discuss new key measures relevant to neuroscience trials. They explore how to integrate and manage imaging and liquid biomarkers in neuroscience therapeutic product development. Collaboration and cooperation between the CRO and laboratories providing specialized services for imaging and biochemical assays are critical to delivering high-quality, regulatory-compliant endpoints within the clinical trial timeline.
Download this webinar to learn key strategies to successfully conduct neuroscience clinical trials through lessons learned from how Medpace works to integrate clinical operations, medical monitoring, central lab, and core lab experts.
Accelerating Global Neuroscience Clinical Development
Neuroscience clinical research is a key therapeutic focus for Medpace, a full-service clinical research organization (CRO). Medpace has extensive experience in phase I-IV neuroscience clinical trials spanning adult and pediatric populations in a wide range of neuroscience indications. Leverage our broad experience in advancing new neuroscience treatments and specialized expertise in the design and management of complex neuroscience programs to keep your trial on time and on budget.